This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessing the Efficacy of Steroid Treatment of Achalasia

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Karthik Ravi, M.D., Mayo Clinic Identifier:
First received: July 16, 2013
Last updated: September 12, 2016
Last verified: September 2016
Would systemic steroids be an effective treatment in early variants of achalasia?

Condition Intervention Phase
Achalasia Drug: Apo-Prednisone Cordorol, Detasone - Prednisone Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia

Resource links provided by NLM:

Further study details as provided by Karthik Ravi, M.D., Mayo Clinic:

Primary Outcome Measures:
  • the proportion of patients with an Eckhart score ≥ 6 at 1 month [ Time Frame: Baseline to 1 month ]

Secondary Outcome Measures:
  • proportion of patients with symptomatic improvement (Eckardt sore 6 or greater) [ Time Frame: baseline to 1 year ]

Estimated Enrollment: 10
Study Start Date: March 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
Drug: Apo-Prednisone Cordorol, Detasone - Prednisone
Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
Other Names:
  • Prednisone
  • Anti-inflamatory
  • Corticosteroid


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Adults ages 18-90 with a diagnosis of achalasia confirmed by findings on esophageal manometry and barium esophagogram will be eligible for the study.
  • Eckardt score6 greater or equal to 6 or 2 or greater for dysphagia and/or regurgitation
  • Symptoms less than 2 years

Exclusion criteria:

  • Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy and injection;
  • Greater than mild esophageal dilation
  • Type 1 achalasia as defined by the Chicago classification scheme7 and/or esophageal diameter > 3cm;
  • Prior treatment for achalasia
  • Use of medications that might affect LES pressure such as anticholinergics or calcium channel antagonists
  • Symptom duration greater than 2 years
  • Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
  • Disorders which predispose to unreliable responses such as Schizophrenia, Alzheimer's disease or significant memory loss
  • Pregnant and lactating females will be excluded as steroids are not thought safe for the fetus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01903486

United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Karthik Ravi, MD Mayo Clinic
  More Information

Responsible Party: Karthik Ravi, M.D., PI, Mayo Clinic Identifier: NCT01903486     History of Changes
Other Study ID Numbers: 12-009825
Study First Received: July 16, 2013
Last Updated: September 12, 2016

Keywords provided by Karthik Ravi, M.D., Mayo Clinic:
Trouble swallowing
disorder of the esophagus

Additional relevant MeSH terms:
Esophageal Achalasia
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on August 16, 2017